Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
ФГБУ «Федеральный медицинский исследовательский центр психиатрии и наркологии им. В.П.Сербского» Минздрава России. 119991, Россия, Москва, Кропоткинский пер., д. 23 marachevm@gmail.com
Список исп. литературыСкрыть список 1. Sit D, Rothschild AJ, Wisner KL. A review of postpartum psychosis. J Women's Health 2006; 15 (4): 352–68. 2. Spinelli M.G. Psychiatric Disorders During Pregnancy and Postpartum. J Am Med Women’s Ass’n 1998; 53: 165. 3. Brockington I. A historical perspective on the psychiatry of motherhood. Perinatal stress, mood and anxiety disorders. Karger Pub 2005; 173: 1–5. 4. Steiner M, Yonkers KA, Eriksson E (ed.). Mood disorders in women. M.Dunitz, 2000. 5. Esquirol É. Des maladies mentales. 1838. 6. Butts HF. Post-partum psychiatric problems. A review of the literature dealing with etiological theories. J National Med Assoc 1969; 61 (2): 136. 7. American Psychiatric Association et al. DSM-II: Diagnostic and Statistical Manual of Mental Disorders. Am Psychiatric Assoc 1975. 8. Frances A et al. Diagnostic and statistical manual of mental disorders: DSM-IV. American Psychiatric Association, 1994. 9. Sit D, Rothschild AJ, Wisner KL. A review of postpartum psychosis. J Women's Health 2006; 15 (4): 352–68. 10. Brockington I. Puerperal psychosis: Motherhood and mental health. New York: Oxford University Press, 1996; р. 200. 11. Wisner KL, Peindl KS, Hanusa BH. Psychiatric episodes in women with young children. J Affect Dis 1995; 34 (1): 1–11. 12. O'Hara MW, Wisner KL. Perinatal mental illness: definition, description and aetiology. Best Pract Res Clin Obstet Gynaecol 2014; 28 (1): 3–12. 13. Maternal mental health and child health and development in low and middle income countries. Report of the WHO meeting. Geneva, World Health Organization, 2008. 14. Oates M. Perinatal maternal mental health services. London, England: Royal College of Psychiatrists, 2000. 15. National Collaborating Centre for Mental Health UK et al. Antenatal and postnatal mental health: the NICE guideline on clinical management and service guidance. British Psychological Society, 2007. 16. Valdimarsdóttir U et al. Psychotic illness in first-time mothers with no previous psychiatric hospitalizations: a population-based study. PLoS Med 2009; 6 (2): e1000013. 17. Viguera AC et al. Risk of recurrence of bipolar disorder in pregnant and nonpregnant women after discontinuing lithium maintenance. Am J Psychiatry 2000; 157 (2): 179–84. 18. Munk-Olsen T et al. New parents and mental disorders: a population-based register study. JAMA 2006; 296 (21): 2582–9. 19. Munk-Olsen T et al. Risks and predictors of readmission for a mental disorder during the postpartum period. Arch General Psychiatry 2009; 66 (2):189–95. 20. Dellicour S, ter Kuile FO, Stergachis A. Pregnancy exposure registries for assessing antimalarial drug safety in pregnancy in malaria-endemic countries. PLoS Med 2008; 5 (9): e187. 21. Källén B. The problem of confounding in studies of the effect of maternal drug use on pregnancy outcome. Obstet Gynecol Int 2011; 2012. 22. Grote NK et al. A meta-analysis of depressionduring pregnancy and the risk of preterm birth, low birth weight, and intrauterine growth restriction. Arch General Psychiatry 2010; 67 (10): 1012–24. 23. Bodén R et al. Risks of adverse pregnancy and birth outcomes in women treated or not treated with mood stabilisers for bipolar disorder: population based cohort study. 2012. 24. Lin HC et al. Maternal schizophrenia and pregnancy outcome: does the use of antipsychotics make a difference? Schizophrenia Res 2010; 116 (1): 55–60. 25. Barnes TRE. Schizophrenia Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2011; 25 (5): 567–620. 26. Ennis ZN, Damkier P. Pregnancy exposure to olanzapine, quetiapine, risperidone, aripiprazole and risk of congenital malformations. A systematic review. Basic Clin Pharmacol Toxicol 2015; 116 (4): 315–20. 27. Bellet F et al. Exposure to aripiprazole during embryogenesis: a prospective multicenter cohort study. Pharmacoepidemiol Drug Saf 2015; 24 (4): 368–80. 28. Toh S et al. Prevalence and trends in the use of antipsychotic medications during pregnancy in the US, 2001–2007: a population-based study of 585,615 deliveries. Arch Women's Mental Health 2013; 16 (2): 149–57. 29. Coughlin CG et al. Obstetric and neonatal outcomes after antipsychotic medication exposure in pregnancy. Obstet Gynecol 2015; 125 (5): 1224–35. 30. Sørensen MJ et al. Risk of Fetal Death after Treatment with Antipsychotic Medications during Pregnancy. PloS One 2015; 10 (7): e0132280. 31. HAPO Study Cooperative Research Group et al. Hyperglycaemia and Adverse Pregnancy Outcome (HAPO) Study: associations with maternal body mass index. BJOG 2010; 117 (5): 575. 32. Wendland EM et al. Gestational diabetes and pregnancy outcomes-a systematic review of the World Health Organization (WHO) and the International Association of Diabetes in Pregnancy Study Groups (IADPSG) diagnostic criteria. BMC 2012; 12 (1): 1. 33. Reis M, Källén B. Maternal use of antipsychotics in early pregnancy and delivery outcome. J Clin Psychopharmacol 2008; 28 (3): 279–88. 34. Bodén R et al. Antipsychotics during pregnancy: relation to fetal and maternal metabolic effects. Arch General Psychiatry 2012; 69 (7): 715–21. 35. Habermann F et al. Atypical antipsychotic drugs and pregnancy outcome: a prospective, cohort study. J Clin Psychopharmacol 2013; 33 (4): 453–62. 36. Peng M et al. Effects of prenatal exposure to atypical antipsychotics on postnatal development and growth of infants: a case-controlled, prospective study. Psychopharmacology 2013; 228 (4): 577–84. 37. Gentile S. Antipsychotic therapy during early and late pregnancy. A systematic review. Schizophrenia Bulletin 2010; 36 (3): 518–44. 38. Kris EB. Children of mothers maintained on pharmacotherapy during pregnancy and postpartum. Cur Ther Res, Clin Experimental 1965; 7 (12): 785–9. 39. Slone D et al. Antenatal exposure to the phenothiazines in relation to congenital malformations, perinatal mortality rate, birth weight, and intelligence quotient score. Am J Obstet Gynecol 1977; 128 (5): 486–8. 40. Batterham RL. National Institute for Health and Care Excellence (2014), Obesity-Identification, assessment and management of overweight and obesity in children, young people an adults, CG43. 41. Wells PG et al. Oxidative damage in chemical teratogenesis. Mutation Res/Fundamental Molecular Mechanisms Mutagenesis 1997; 396 (1): 65–78. 42. Holmes LB et al. The teratogenicity of anticonvulsant drugs. N Engl J Med 2001; 344 (15): 1132–8. 43. Meador KJ et al. Pregnancy registries in epilepsy A consensus statement on health out-comes. Neurology 2008; 71 (14): 1109–17. 44. Jentink J et al. Intrauterine exposure to carbamazepine and specific congenital malformations: systematic review and case-control study. BMJ 2010; 341: c6581. 45. Jentink J et al. Valproic acid mono-therapy in pregnancy and major congenital malformations. N Engl J Med 2010; 362 (23): 2185–93. 46. Hunt SJ, Craig JJ, Morrow JI. Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology 2009; 72 (12): 1108–9. 47. Holmes LB et al. Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology 2008; 70 (22). Part 2: 2152–8. 48. Dolk H et al. Does lamotrigine use in pregnancy increase orofacial cleft risk relative to other malformations? Neurology 2008; 71 (10): 714–22. 49. Cunnington MC et al. Final results from 18 years of the International Lamotrigine Pregnancy Registry. Neurology 2011; 76 (21): 1817–23. 50. Bromley RL et al. Early cognitive development in children born to women with epilepsy: a pro-spective report. Epilepsia 2010; 51 (10): 2058–65. 51. Meador KJ et al. Fetal antiepileptic drug exposure and cognitive function at age 3. N Engl J Med 2009; 360: 1597–605. 52. Adab N et al. The long-er term outcome of children born to mothers with epilepsy. J Neurology, Neurosurg Psychiatry 2004; 75 (11): 1575–83. 53. Meador KJ et al. Fetal antiepileptic drug exposure and cognitive out-comes at age 6 years (NEAD study): a prospective observational study. Lancet Neurol 2013; 12 (3): 244–52. 54. Bromley RL et al. The prevalence of neurodevel-opmental disorders in children prenatally exposed to antiepileptic drugs. J Neurol, Neurosurg Psychiatry 2013; 84 (6): 637–43. 55. Christensen J et al. Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA 2013; 309 (16): 1696–703. 56. Wood AG et al. Prospective assessment of autism traits in children exposed to antiepileptic drugs during pregnancy. Epilepsia 2015; 56 (7): 1047–55. 57. Perucca P, Camfield P, Camfield C. Does gender influence susceptibility and consequences of acquired epilepsies? Neurobiol Dis 2014; 72: 125–30. 58. Weinstein MR. Lithium treatment of women during pregnancy and in the post-delivery period. Handbook Lithium Ther. Springer Netherlands, 1980; р. 421–30. 59. Diav-Citrin O. et al. Pregnancy outcome following in utero exposure to lithium: a prospective, comparative, observational study. Am J Psychiatry 2014. 60. Ornoy A, Yacobi S. Lithium and pregnancy Response. Israel J Psychiatry Related Sci 2008; 45 (4): 301. 61. McKnight RF et al. Lithium toxicity profile: a systematic review and meta-analysis. Lancet 2012; 379 (9817): 721–8. 62. Schou M. What happened later to the lithium babies? A follow‐up study of children born without malformations. Acta Psychiatr Scand 1976; 54 (3): 193–7. 63. American college of obstetricians and gynecologists 2007, practice bulletin number 87. http://www.ncbi.nlm.nih.gov/pubmed/ 17978143 64. Morrow JI et al. Folic acid use and major congenital malformations in offspring of women with epilepsy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol, Neurosurg Psychiatry 2009; 80 (5): 506–11. 65. Jentink J et al. Does folic acid use decrease the risk for spina bifida after in utero exposure to valproic acid? Pharmacoepidemiol Drug Safety 2010; 19 (8): 803–7. 66. Wlodarczyk BJ et al. Antiepileptic drugs and pregnancy outcomes. Am J Med Genetics. Part A 2012; 158 (8): 2071–90. 67. European Medicines Agency (EMA). http:// www.ema.europa.eu /ima/index.jsp?curl=pages/ news_and_events/news/2014/10/ news _detail_002186. jsp&mid=WC0b01ac058004d5c1 68. NICE Clinical Guideline 192. 2014. http://www.nice.org.uk/guidance/cg192. National Institute for Health and Care Excellence. 69. Charlton RA et al. Selective serotonin reuptake inhibitor prescribing before, during and after pregnancy: a population‐based study in six European regions. BJOG 2015; 122 (7): 1010–20. 70. Grigoriadis S et al. The impact of maternal depression during pregnancy on perinatal outcomes: a systematic review and meta-analysis. J Clin Psychiatry 2013; 74 (4): 321–41. 71. Huybrechts KF et al. Antidepressant use in pregnancy and the risk of cardiac defects. N Engl J Med 2014; 370 (25): 2397–407. 72. Furu K et al. Selective serotonin reuptake inhibitors and venlafaxine in early pregnancy and risk of birth defects: population based cohort study and sibling design. BMJ 2015; 350: h1798. 73. Bellantuono C et al. The safety of serotonin-noradrenaline reuptake inhibitors (SNRIs) in pregnancy and breastfeeding: a comprehensive review. Hum Psychopharmacol: Clin Experimental 2015; 30 (3): 143–51. 74. Lassen D, Ennis ZN, Damkier P. First‐Trimester Pregnancy Exposure to Venlafaxine or Duloxetine and Risk of Major Congenital Malformations: A Systematic Review. Basic Clin Pharmacol Toxicol 2016; 118 (1): 32–6. 75. Huybrechts KF et al. Preterm birth and antidepressant medication use during pregnancy: a systematic review and me-ta-analysis. PLoS One 2014; 9 (3): e92778. 76. Grigoriadis S et al. Prenatal exposure to antidepressants and persistent pulmonary hypertension of the newborn: systematic review and meta-analysis. BMJ 2014; 348: f6932. 77. Huybrechts KF et al. Antidepressant use late in preg-nancy and risk of persistent pulmonary hypertension of the newborn. JAMA 2015; 313 (21): 2142–51. 78. Grigoriadis S et al. Antidepressant exposure during pregnancy and congenital malformations: is there an association? A systematic review and meta-analysis of the best evidence. J Clin Psychiatry 2013; 74 (4): e293–e308. 79. Forsberg L et al. Neonatal Adaptation in Infants Prenatally Exposed to Antidepressants-Clinical Monitoring Using Neonatal Abstinence Score. PloS One 2014; 9 (11): e111327. 80. Man KKC et al. Exposure to selective serotonin reuptake inhibitors during pregnancy and risk of autism spectrum disorder in children: A systematic review and meta-analysis of observational studies. Neurosci Biobehavioral Rev 2015; 49: 82–9. 81. Christensen J, Parner ET, Vestergaard M. Antidepressant exposure in pregnancy and risk of autism spectrum disorders. Clin Epidemiol 2013; 5: 449–59. 82. Boukhris T et al. Antidepressant use during pregnancy and the risk of autism spectrum disorder in children. JAMA Pediatr 2015; р. 1–8. 83. Castro VM et al. Absence of evidence for increase in risk for autism or attention-deficit hyperactivity disorder following antidepressant exposure during pregnancy: a replication study. Translational Psychiatry 2016; 6 (1): e708. 84. Nulman I et al. Neurodevelopment of children following prenatal exposure to venlafaxine, selective serotonin reuptake inhibitors, or untreated maternal depression. Am J Psychiatry 2012; 169 (11): 1165–74. 85. Santucci AK et al. Impact of prenatal exposure to serotonin reuptake inhibitors or maternal major depressive disorder on infant developmental outcomes. J Clin Psychiatry 2014; 75 (10): 1088–95. 86. Handal M et al. Motor development in children prenatally exposed to selective serotonin reuptake inhibitors: a large population‐based pregnancy cohort study. BJOG 2016; 123 (12): 1908–17. 87. Rounds M. The fetal safety of benzodiazepines: an updated meta-analysis. J Obstet Gynaecol Can 2011; 33 (1): 46–8. 88. Ban L et al. First trimester exposure to anxiolytic and hypnotic drugs and the risks of major congenital anomalies: a United Kingdom population-based cohort study. PloS One 2014; 9 (6): e100996. 89. Wikner BN, Källén B. Are hypnotic benzodiazepine receptor agonists teratogenic in humans? J Clin Psychopharmacol 2011; 31 (3): 356–9. 90. Wang LH et al. Increased risk of adverse pregnancy out-comes in women receiving zolpidem during pregnancy. Clinl Pharmacol Ther 2010; 88 (3). 91. World health organization. Global strategy for infant and young child feeding. Geneva, 2003. 92. Hale TW, Hilary E. Rowe. Medications and mothers' milk. Pharmasoft Medical Pub., 2004. Lutz UC et al. Aripiprazole in pregnancy and lactation: a case report. J Clin Psychopharmacol 2010; 30 (2): 204–5. 93. Teoh S et al. Estimation of rac-amisulpride transfer into milk and of infant dose via milk during its use in a lactating woman with bipolar disorder and schizophrenia. Breastfeeding Med 2011; 6 (2): 85–8. 94. Dev VJ, Krupp P. Adverse event profile and safety of clozapine. Rev Contemp Pharmacother 1995; 6: 197–208. 95. Tripathi BM, Majumder P. Lactating mother and psychotropic drugs. Mens Sana Monographs 2010; 8 (1): 83. 96. Oystein Berle J, Spigset O. Antidepressant use during breastfeeding. Cur Women's Health Rev 2011; 7 (1): 28–34. 97. Sivertz K, Kostaras X. The use of psychotropic medications in pregnancy and lactation. BC Med J 2005; 47: 135–8. 98. Burt VK et al. The use of psychotropic medications during breast-feeding. Am J Psychiatry 2001; 158 (7): 1001–9.